Company intelligence / Profile preview

Sungen Biomedical

Beijing, Beijing Municipality, Chinasungenbiomed.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company’s lead monoclonal antibody program, SGC001, is the world’s first antibody drug targeting acute myocardial infarction. It has received FDA Fast Track Designation based on favorable safety/tolerability data from healthy volunteer studies. The designation is expected to accelerate development and commercialization.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodies (BsAbs)Antibody-drug conjugates (ADCs)Antibody–oligonucleotide conjugates (AOCs)
Industry: Biotech

Drug pipeline

1 asset

SGC001

Partnerships

No major pharma partnerships disclosed as of May 2025.

Beyond the preview

Go deeper on Sungen Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sungen Biomedical.